STOCK TITAN

Harmony Biosciences Holdings Inc - HRMY STOCK NEWS

Welcome to our dedicated news page for Harmony Biosciences Holdings (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harmony Biosciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harmony Biosciences Holdings's position in the market.

Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) will report its first quarter 2024 financial results on April 30, 2024. The company will host a conference call and live webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
conferences earnings
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) announced an exclusive licensing agreement with Bioprojet to develop and commercialize a new orexin-2 receptor agonist, TPM-1116, for narcolepsy and other sleep/wake disorders. The agreement aims to accelerate development and potentially offer a best-in-class clinical profile, strengthening Harmony's position in the sleep/wake space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
none
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. initiates Phase 3 trial for pitolisant in patients with Prader-Willi syndrome, aiming to address excessive daytime sleepiness and behavioral symptoms. FDA grants Orphan Drug Designation, providing incentives for rare disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) to participate in fireside chat at Needham Virtual Healthcare Conference. Webcast available on Harmony's investor page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) announced its participation in upcoming investor conferences like Leerink Partners Global Biopharma Conference and Barclays Global Healthcare Conference. The management team will engage in fireside chats on March 11 and 12, 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. reports net revenue growth of over 30% for the fourth quarter and full year 2023, with WAKIX® generating $168.4 million and $582.0 million, respectively. The FDA granted priority review for WAKIX in pediatric narcolepsy, with a PDUFA date of June 21, 2024. Harmony also received Orphan Drug Designation for pitolisant to treat Prader-Willi Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. receives FDA priority review for WAKIX® tablets for pediatric narcolepsy treatment, with a PDUFA date set for June 21, 2024. The FDA's decision accelerates the approval process for a new treatment option, highlighting the urgent need for innovative therapies in pediatric narcolepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary
Harmony Biosciences Receives FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will report fourth quarter and full year 2023 financial results on February 22, 2024. A conference call and live webcast will be hosted to discuss the results. The call details and webcast link are available on the investor page of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
conferences earnings
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported preliminary net revenue of ~$168 million for the fourth quarter and ~$582 million for the full year 2023, representing growth of ~31% and ~33%, respectively. The average number of patients on WAKIX increased to ~6,150, with 2024 net product revenue projected between $700 -$720 million. The company also announced a $50 million common stock repurchase in the fourth quarter, bringing the 2023 total to $100 million, with plans to continue opportunistic share repurchases in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
Harmony Biosciences Holdings Inc

Nasdaq:HRMY

HRMY Rankings

HRMY Stock Data

1.68B
34.79M
19.38%
90.04%
11.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Plymouth Meeting

About HRMY

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.